Jump to content
Powered by

NanoDex Inc.

NanoDex is an R&D venture company located in Ebina, Kanagawa Prefecture, JAPAN. It was established in August, 2008, and the capital is 3 million Yen (~245 T€). Founder and director is Dr Kenjiro HATTORI. The core technology of NanoDex is the synthesis and application of folate-modified cyclodextrins (ND1) as “artificial cancer antibodies”.

In this technology up to seven folates were attached to cyclodextrin with a spacer, forming a "nanocluster" and "sea anemone" type structure which interacts with folate receptor proteins which are specific for cancer cells. Thus, if the cyclodextrin cavity is loaded with an imaging or anti-cancer reagent, a tumor-specific signal or apoptotic effect can be achieved ("artificial anticancer antibody").

Folate-modified cyclodextrins (ND1) as "artificial cancer antibody" by NanoDex © NanoDex Inc.

The concept was successfully proven in animals with tetramethylrhodamine isothiocyanate and with amidetrizoic acid (Urografin ™, a Bayer-Schering dye) as fluorescent markers for 3D CT endoscopic imaging of stomach and lung cancers, and with doxorubicin for KB cells. A patent portfolio has been established.
NanoDex Inc. offers collaboration for the development of innovative anti-cancer drug and cancer contrast medicines and can offer test samples, research contracts and patent licenses.

For inquiries, please contact:
Dr. Kenjiro Hattori
NanoDex Inc.
Kanagawa Industrial Technology Center 1F1-2
705-1 Imaizumi, Ebina
Kanagawa 243-0435
JAPAN
Fax: +81-46-244-0595

E-mail: kh0427@cityfujisawa.ne.jp
Internet: https://www.gesundheitsindustrie-bw.dewww.nanodex.jp/english/

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodex-inc